| Literature DB >> 35880506 |
Hoon Kim1,2, Mee-Hwa Lee3, Dong-Yun Lee4, Hyein Kim2, Hyun Jung Lee3, Miran Kim5, Joo Hyun Park6, Bo Hyon Yun7, Sa Ra Lee8, Hyun Hee Cho9, Byung Moon Kang8.
Abstract
BACKGROUND: This study was performed to evaluate etiologies and secular trends in primary amenorrhea in South Korea.Entities:
Keywords: Etiology; Gonadal Dysgenesis; Müllerian Agenesis; Primary Amenorrhea
Mesh:
Year: 2022 PMID: 35880506 PMCID: PMC9313977 DOI: 10.3346/jkms.2022.37.e230
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 5.354
Fig. 1Study population.
Diagnostic distribution of primary amenorrhea, 2000–2016
| Diagnosis | Number (%) | Age at first diagnosis, yr | ||||
|---|---|---|---|---|---|---|
| Mean ± SD | Range | |||||
| Hypergonadotropic hypogonadism | 226 (26.40) | 17.58 ± 5.35 | 0–30 | |||
| Gonadal dysgenesis | 192 (22.43) | 17.48 ± 5.52 | 0–30 | |||
| 1) 46, XX | 65 (7.59) | 18.60 ± 3.87 | 14–29 | |||
| 2) 46, XY | 12 (1.40) | 18.67 ± 4.44 | 13–28 | |||
| 3) Turner syndrome | 110 (12.85) | 16.57 ± 6.33 | 0–30 | |||
| 45, X | 55 (6.43) | 15.53 ± 7.00 | 0–30 | |||
| Mosaic | 35 (4.09) | 16.68 ± 5.74 | 1–30 | |||
| Structural | 17 (1.99) | 19.00 ± 4.86 | 13–29 | |||
| Isochromosome | 3 (0.35) | 18.67 ± 4.73 | 15–24 | |||
| 4) Others | 5 (0.58) | 20.20 ± 3.56 | 17–25 | |||
| 17α-hydroxylase deficiency (46, XX) | 4 (0.47) | 21.00 ± 3.56 | 18–25 | |||
| Kearn-Sayre syndrome | 1 (0.12) | 17.00 ± 0.00 | 17 | |||
| Irradiation/Chemotherapy/Immunotherapy | 16 (1.87) | 17.38 ± 4.18 | 13–25 | |||
| Post-ovarian surgery | 3 (0.35) | 17.33 ± 2.08 | 15–19 | |||
| Unknown etiology | 15 (1.75) | 19.00 ± 4.78 | 13–30 | |||
| Hypogonadotropic hypogonadism | 220 (25.70) | 18.62 ± 3.90 | 13–30 | |||
| Kallmann syndrome/idiopathic hypogonadotropic hypogonadism | 48 (5.61) | 20.79 ± 4.31 | 14–30 | |||
| Organic cause | 39 (4.56) | 17.82 ± 4.28 | 13–30 | |||
| 1) Space occupying lesion | 23 (2.69) | 16.96 ± 3.74 | 13–28 | |||
| Craniopharyngioma | 8 (0.93) | 17.13 ± 2.80 | 13–21 | |||
| Germinoma | 5 (0.58) | 15.40 ± 2.19 | 13–19 | |||
| Astrocytoma | 3 (0.35) | 18.33 ± 4.51 | 14–23 | |||
| Rathke’s cleft cyst | 3 (0.35) | 18.67 ± 8.08 | 14–28 | |||
| Unconfirmed | 4 (0.47) | 16.25 ± 3.30 | 13–20 | |||
| 2) Panhypopituitarism | 9 (1.05) | 21.78 ± 4.79 | 15–30 | |||
| 3) Pituitary injury | 4 (0.47) | 16.25 ± 1.26 | 15–18 | |||
| 4) Prader-Willi syndrome | 2 (0.23) | 14.00 ± 0.00 | 14 | |||
| 5) Microcephaly | 1 (0.12) | 16.00 ± 0.00 | 16 | |||
| Thyroid dysfunction | 2 (0.23) | 15.50 ± 0.71 | 15–16 | |||
| 1) Hyperthyroidism | 1 (0.12) | 15.00 ± 0.00 | 15 | |||
| 2) Hypothyroidism | 1 (0.12) | 16.00 ± 0.00 | 16 | |||
| Hyperprolactinemia | 10 (1.17) | 17.40 ± 0.97 | 16–19 | |||
| 1) Prolactinoma (> 10 mm) | 8 (0.93) | 17.38 ± 1.06 | 16–19 | |||
| 2) Normal pituitary magnetic resonance imaging | 2 (0.23) | 17.50 ± 0.71 | 17–18 | |||
| Functional cause | 10 (1.17) | 17.30 ± 2.41 | 15–23 | |||
| 1) Nutrition related | 5 (0.58) | 16.60 ± 1.52 | 15–19 | |||
| 2) Exercise related | 3 (0.35) | 17.00 ± 1.73 | 15–18 | |||
| 3) Stress related | 1 (0.12) | 16.00 ± 0.00 | 16 | |||
| 4) Unknown etiology | 1 (0.12) | 23.00 ± 0.00 | 23 | |||
| Constitutional delay | 36 (4.21) | 15.64 ± 1.25 | 13–19 | |||
| Unknown etiology | 75 (8.76) | 19.51 ± 3.62 | 15–30 | |||
| Eugonadism | 341 (39.84) | 18.90 ± 4.48 | 10–30 | |||
| Outflow tract abnormality | 265 (30.96) | 19.32 ± 4.78 | 10–30 | |||
| 1) Müllerian agenesis (MRKH) | 224 (26.17) | 20.25 ± 4.48 | 11–30 | |||
| 2) Isolated cervical agenesis/atresia | 4 (0.47) | 12.75 ± 2.22 | 11–16 | |||
| 3) Isolated uterine agenesis/defect | 6 (0.70) | 18.17 ± 2.79 | 15–23 | |||
| 4) Partial vaginal agenesis | 5 (0.58) | 13.80 ± 1.48 | 12–16 | |||
| 5) Transverse vaginal septum | 4 (0.47) | 15.75 ± 4.19 | 10–20 | |||
| 6) Imperforate hymen | 22 (2.57) | 13.18 ± 1.18 | 11–16 | |||
| Anovulation | 76 (8.88) | 17.43 ± 2.79 | 14–27 | |||
| 1) Polycystic ovarian syndrome | 75 (8.76) | 17.31 ± 2.58 | 14–27 | |||
| 2) Late-onset congenital adrenal hyperplasia | 1 (0.12) | 27.00 ± 0.00 | 27 | |||
| DSD | 69 (8.06) | 17.74 ± 5.06 | 0–29 | |||
| XX DSD | 8 (0.93) | 16.00 ± 7.07 | 0–24 | |||
| 21-hydroxylase deficiency | 6 (0.70) | 15.67 ± 8.24 | 0–24 | |||
| 11-hydroxylase deficiency | 1 (0.12) | 15.00 ± 0.00 | 15 | |||
| Intrauterine androgen exposure | 1 (0.12) | 19.00 ± 0.00 | 19 | |||
| XY DSD | 39 (4.56) | 18.38 ± 4.54 | 9–29 | |||
| Complete AIS | 32 (3.74) | 18.44 ± 4.51 | 9–29 | |||
| Partial AIS | 6 (0.70) | 18.17 ± 5.53 | 15–29 | |||
| 17α-hydroxylase deficiency (46 XY) | 1 (0.12) | 18.00 ± 0.00 | 18 | |||
| Sex chromosomal DSD | 11 (1.29) | 17.55 ± 4.66 | 13–27 | |||
| Incomplete assessment | 11 (1.29) | 16.91 ± 5.86 | 5–27 | |||
| Total | 856 (100.00) | 18.38 ± 4.67 | 0–30 | |||
SD = standard deviation, MRKH = Mayer-Rokitansky-Küster-Hauser, DSD = disorders of sex development, AIS = androgen insensitivity syndrome.
Baseline characteristics according to the diagnosis of primary amenorrhea
| Variables | All (n = 856) | Hypergonadotropic hypogonadism (n = 226) | Hypogonadotropic hypogonadism (n = 220) | Eugonadism (n = 341) | Disorders of sex development (n = 69) | |
|---|---|---|---|---|---|---|
| Age at diagnosis, yr | 17 (15–21) | 17 (15–21) | 18 (16–21) | 18 (16–22) | 16 (15–20) | 0.022 |
| Height, cm | 159.7 (153–164) | 153.0 (143.7–160.8)a,b,c | 161.0 (155.0–166.0)a | 160.0 (156.0–164.0)b | 162.5 (156.3–167.0)c | < 0.001 |
| Weight, kg | 51.1 (45.9–58.0) | 49.1 (41.1–57.0)a,b | 51.5 (45.7–60.0)a | 53.0 (48.0–59.0)b | 52.4 (46.0–60.0) | < 0.001 |
| Body mass index, kg/m2 | 20.3 (18.4–23.0) | 20.5 (18.3–23.4) | 19.9 (18.2–22.7) | 20.7 (19.0–23.0) | 20.4 (18.1–23.3) | 0.126 |
P by Kruskall-Wallis test.
a,b,cP by Bonferroni’s correction < 0.05/6 = 0.008.
Secular trends in primary amenorrhea by diagnosis
| Diagnosis | 2000–2006 (n = 193) | 2007–2011 (n = 269) | 2012–2016 (n = 394) | Total | |
|---|---|---|---|---|---|
| Hypergonadotropic hypogonadism | |||||
| Gonadal dysgenesis | 56 (29.0%) | 58 (21.6%) | 78 (19.8%) | 192 (22.4%) | |
| Irradiation/Chemotherapy/Immunotherapy | 1 (0.5%) | 2 (0.7%) | 13 (3.3%) | 16 (1.9%) | |
| Post-ovarian surgery | 1 (0.5%) | 2 (0.7%) | 0 (0%) | 3 (0.4%) | |
| Unknown etiology | 1 (0.5%) | 2 (0.7%) | 12 (3.1%) | 15 (1.8%) | |
| Hypogonadotropic hypogonadism | |||||
| Kallmann syndrome/idiopathic hypogonadotropic hypogonadism | 13 (6.7%) | 13 (4.8%) | 22 (5.6%) | 48 (5.6%) | |
| Organic cause | 5 (2.6%) | 14 (5.2%) | 20 (5.1%) | 39 (4.6%) | |
| Thyroid dysfunction | 0 (0%) | 2 (0.7%) | 0 (0%) | 2 (0.2%) | |
| Hyperprolactinemia | 4 (2.1%) | 1 (0.4%) | 5 (1.3%) | 10 (1.2%) | |
| Functional cause | 2 (1.0%) | 3 (1.1%) | 5 (1.3%) | 10 (1.2%) | |
| Constitutional delay | 6 (3.1%) | 13 (4.8%) | 17 (4.3%) | 36 (4.2%) | |
| Unknown etiology | 20 (10.4%) | 30 (11.2%) | 25 (6.4%) | 75 (8.8%) | |
| Eugonadism | |||||
| Outflow tract abnormality | 54 (28.0%) | 90 (33.5%) | 121 (30.7%) | 265 (31.0%) | |
| Anovulation | 11 (5.7%) | 19 (7.1%) | 46 (11.7%) | 76 (8.9%) | |
| Disorders of sex development | |||||
| XX DSD | 1 (0.5%) | 4 (1.5%) | 3 (0.8%) | 8 (0.9%) | |
| XY DSD | 8 (4.2%) | 12 (4.5%) | 19 (4.8%) | 39 (4.6%) | |
| Sex chromosomal DSD | 7 (3.6%) | 0 (0%) | 4 (1.0%) | 11 (1.3%) | |
| Incomplete assessment | 3 (1.6%) | 4 (1.5%) | 4 (1.0%) | 11 (1.3%) | |
DSD = disorders of sex development.